Search Within

Craig Moskowitz

Formats
  1. Meeting Abstract (229)
  2. Journal Article (174)
  3. Book Section (3)
  4. Research Letter (1)
Groups
  1. Department of Medicine (407)
  2. Hematologic Malignancies, Division of (407)
  3. Center for Hematologic Malignancies (288)
  4. Lymphoma (273)
  5. Survivorship Research (176)
  6. Epidemiology and Biostatistics (103)

More Groups

People
  1. Andrew Zelenetz (207)
  2. David Straus (117)
  3. Paul Hamlin (113)
  4. Carol Portlock (106)
  5. Ariela Noy (94)
  6. Matthew Matasar (91)

More People

Years
  1. 2024 (1)
  2. 2023 (2)
  3. 2022 (3)
  4. 2021 (4)
  5. 2020 (6)
  6. 2019 (8)

More Years

Publications
  1. Blood (160)
  2. Journal of Clinical Oncology (46)
  3. Biology of Blood and Marrow Transplantation (23)
  4. Annals of Oncology (17)
  5. British Journal of Haematology (17)
  6. Haematologica (16)

More Publications

Publishers
  1. American Society of Hematology (165)
  2. American Society of Clinical Oncology (46)
  3. Elsevier Inc. (44)
  4. Oxford University Press (20)
  5. John Wiley & Sons (18)
  6. Ferrata Storti Foundation (16)

More Publishers

Results (407)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase II clinical experience with the proteasome inhibitor PS-341 in patients with indolent lymphomas
    Meeting Abstract

    O'Connor, O. A.; Moskowitz, C. H.; Wright, J. J.; Macgregor-Cortelli, B.; Straus, D.; Furst, D.; Horse-Grant, D.; Schenkein, D. P.; Zelenetz, A. D.
    Blood (2002)

    Fulltext@MSK | Save
  • An analysis of accelerated full course chemotherapy followed by upfront high dose therapy (HDT) and autologous stem cell transplantation (ASCT) for patients with International Prognostic Index IV (IPI IV) aggressive NHL
    Meeting Abstract

    Moskowitz, C. H.; Kewalramani, T.; Donnelly, G.; Zelenetz, A. D.; Noy, A.; Rice, D.; Kuznetsov, M.; Straus, D.; Nimer, S. D.; Portlock, C. S.
    Blood (2002)

    Fulltext@MSK | Save
  • Similar outcomes for chemosensitive (CS) relapsed or primary refractory peripheral T-cell lymphoma (PTCL) and diffuse large B-cell lymphoma (DLBCL) treated with autologous transplantation (ASCT)
    Meeting Abstract

    Kewalramani, T.; Nimer, S. D.; Zelenetz, A. D.; Hamlin, P. A.; Horwitz, S.; Qin, J.; Malhotra, S.; Yahalom, J.; Moskowitz, C. H.
    Blood (2002)

    Fulltext@MSK | Save
  • Gemicitabine/vinorelbine - A well tolerated and effective regimen for patients with relapsed/refractory Hodgkin's disease (RD) who fail autologous stem cell transplantation (ASCT)
    Meeting Abstract

    Hamlin, P. A.; Kewalramani, T.; Schaindlin, P.; Moskowitz, C. H.
    Blood (2002)

    Fulltext@MSK | Save
  • Autologous transplantation (ASCT) with total body irradiation (TBI) based conditioning appears superior to chemotherapy only (Non-TBI) conditioning for patients with relapsed or primary refractory chemosensitive (CS) diffuse large B-cell lymphoma (DLBCL) who have no extranodal sits (ENS) of disease (dz)
    Meeting Abstract

    Kewalramani, T.; Moskowitz, C. H.; Zelenetz, A. D.; Malhotra, S.; Qin, J.; Yahalom, J.; Nimer, S. D.
    Blood (2002)

    Fulltext@MSK | Save
  • Clinical experience of the histone deacetylase inhibitor suberoylanalide hydroxamic acid (SAHA) in heavily pre-treated patients with aggressive non-Hodgkin's lymphoma (NHL) and Hodgkin's disease (HD)
    Meeting Abstract

    O'Connor, O. A.; Richon, V.; Moskowitz, C. H.; Zelenetz, A. D.; Macgregor-Cortelli, B.; Curly, T.; Richardson, S.; Tong, W.; Rifkind, R.; Marks, P.; more...
    Blood (2002)

    Fulltext@MSK | Save
  • H. pylori-independent MALT lymphoma of the stomach: Excellent outcome with radiation alone
    Meeting Abstract

    Yahalom, J.; Portlock, C. S.; Gonzales, M.; Moskowitz, C. H.; Noy, A.; Straus, D. J.; Zelenetz, A. D.
    Blood (2002)

    Fulltext@MSK | Save
  • Risk-adapted therapy for relapsed and refractory lymphoma using ICE chemotherapy
    Journal Article

    Moskowitz, C.
    Cancer Chemotherapy and Pharmacology (2002)

    Fulltext@MSK | Save
  • Rituximab for aggressive non-Hodgkin's lymphomas relapsing after or refractory to autologous stem cell transplantation
    Journal Article

    Pan, D.; Moskowitz, C. H.; Zelenetz, A. D.; Straus, D.; Kewalaramani, T.; Noy, A.; Qin, J.; Teruya-Feldstein, J.; Portlock, C. S.
    The Cancer Journal (2002)

    Fulltext@MSK | Save
  • Results of a prospective randomized trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) alone vs. ABVD plus radiation therapy for early stage non bulky Hodgkin's disease
    Meeting Abstract

    Straus, D. J.; Yahalom, J.; Zelenetz, A. D.; Qin, J.; Myers, J.; Moskowitz, C. H.; Noy, A.; Bertino, J. R.; Portlock, C. S.
    Blood (2001)

    Fulltext@MSK | Save